M. Kalpana Devi
M. Kalpana Devi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aiswarya Nair U.
Sri Shanmugha College of Pharmacy Department of Pharmacy Practice Salem India
1 shared publication - Akshaya Krishnan
Excel College of Pharmacy Namakkal India
1 shared publication - Anand Kumar S.
Sri Shanmugha College of Pharmacy Department of Pharmacy Practice Salem India
1 shared publication - Balakrishnan Sangameswaran
SSM College of Pharmacy, Jambai, Bhavani(T.K) Erode (Dt), Tamil Nadu, 638312, India
1 shared publication - Chindambaram Kannaiyan Dhanapal
Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Annamalai Nagar,Tamilnadu, 608002, India
1 shared publication - Gokilavani S
Sri Shanmugha College of Pharmacy Department of Pharmacology Salem India
1 shared publication
Latest Publications
- 27 March 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmacogenomics and Personalized Medicine
- Vol. 23
Model-Informed Precision Dosing of Thiopurines in Inflammatory Bowel Disease through Pharmacometric Integration of TPMT and NUDT15 Genotypes
Introduction/Objective: Thiopurines (azathioprine, 6-mercaptopurine) are pivotal for IBD remission induction but possess a narrow therapeutic index and large PK/PD variability. We assess integrating TPMT and NUDT15 genotyping with pharmacometric models to support genotype-directed, model-informed precision dosing beyond empiric approaches and traditional therapeutic drug monitoring. Methods: We performed a narrative review of pharmacometric and pharmacogenetic research, evaluating (i) genotype–phenotype correlation for TPMT and NUDT15 by ancestry; (ii) population PK/PD and Bayesian or nonlinear mixed-effects modeling with genetic, biochemical, and co-medication covariates; and (iii) biomarker approaches comparing red-cell 6-thioguanine nucleotide assays vs. DNA-thioguanine, and clinical outcomes. Results: NUDT15 R139C alleles impart high early-onset leukopenic risk at nominal doses, particularly in East/South Asians, challenging genotype-blind dosing and conventional 6-TGN–based monitoring. TPMT polymorphisms, despite their traditional prominence, exhibit genotype–phenotype discordance and diminished predictive value outside of primarily Caucasian populations. Bayesian and mixed-effects models of the present day provide individualized dosing in real time; however, widely generalizable, genotype-normalized PK/PD paradigms and routine inclusion of higher-resolution biomarkers like DNA-TG are limited. Discussion: Dependence on historic TDM and TPMT-favoring strategies is inadequate in heterogeneous populations and for NUDT15 variant-associated early toxicity. Incorporation of diplotype-directed MIPD with solid PK/PD modeling and improved biomarkers may change thiopurine treatment from dose-measure-reactive to dose-predictive. Challenges involve ancestry-sensitive algorithms, standardized DNA-TG assays, and EHR-based, validated decision support. Conclusion MIPD combining TPMT/NUDT15 diplotypes, adaptive PK/PD modeling, and high-resolution biomarkers can make thiopurine treatment in IBD a modernized reality. Widespread implementation necessitates ancestry-adapted, clinically established algorithms, decision support, and multicenter testing to provide safe, effective, and equitable dosing.
- 27 March 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmacogenomics and Personalized Medicine
- Vol. 23
Model-Informed Precision Dosing of Thiopurines in Inflammatory Bowel Disease through Pharmacometric Integration of TPMT and NUDT15 Genotypes
Introduction/Objective: Thiopurines (azathioprine, 6-mercaptopurine) are pivotal for IBD remission induction but possess a narrow therapeutic index and large PK/PD variability. We assess integrating TPMT and NUDT15 genotyping with pharmacometric models to support genotype-directed, model-informed precision dosing beyond empiric approaches and traditional therapeutic drug monitoring. Methods: We performed a narrative review of pharmacometric and pharmacogenetic research, evaluating (i) genotype–phenotype correlation for TPMT and NUDT15 by ancestry; (ii) population PK/PD and Bayesian or nonlinear mixed-effects modeling with genetic, biochemical, and co-medication covariates; and (iii) biomarker approaches comparing red-cell 6-thioguanine nucleotide assays vs. DNA-thioguanine, and clinical outcomes. Results: NUDT15 R139C alleles impart high early-onset leukopenic risk at nominal doses, particularly in East/South Asians, challenging genotype-blind dosing and conventional 6-TGN–based monitoring. TPMT polymorphisms, despite their traditional prominence, exhibit genotype–phenotype discordance and diminished predictive value outside of primarily Caucasian populations. Bayesian and mixed-effects models of the present day provide individualized dosing in real time; however, widely generalizable, genotype-normalized PK/PD paradigms and routine inclusion of higher-resolution biomarkers like DNA-TG are limited. Discussion: Dependence on historic TDM and TPMT-favoring strategies is inadequate in heterogeneous populations and for NUDT15 variant-associated early toxicity. Incorporation of diplotype-directed MIPD with solid PK/PD modeling and improved biomarkers may change thiopurine treatment from dose-measure-reactive to dose-predictive. Challenges involve ancestry-sensitive algorithms, standardized DNA-TG assays, and EHR-based, validated decision support. Conclusion MIPD combining TPMT/NUDT15 diplotypes, adaptive PK/PD modeling, and high-resolution biomarkers can make thiopurine treatment in IBD a modernized reality. Widespread implementation necessitates ancestry-adapted, clinically established algorithms, decision support, and multicenter testing to provide safe, effective, and equitable dosing.
- 16 March 2026
- Published by Bentham Science Publishers Ltd. in Current Nanomedicine
- Vol. 16, 1-13
Clinical Translation Potential of Surface-Modified Proniosomes in Systemic Cancer Therapeutics
Proniosomes are anhydrous, non-ionic surfactant precursors that rehydrate into bilayered niosomes, addressing long-standing challenges in systemic cancer drug delivery. We systematically reviewed oncology-targeted proniosome publications, comparing drug loading, stability, release, and pharmacokinetics with liposomes, polymeric nanoparticles, micelles, and solid-lipid nanoparticles. We assessed design determinants (surfactant composition, cholesterol ratio, charge inducers), surface modifications (PEGylation, ligand conjugation, pH- or thermoresponsive groups), and conducted a SWOT analysis. Proniosomes demonstrated high physicochemical stability, robust encapsulation, and controlled release, supporting hydrophilic, hydrophobic, and macromolecular payloads. Self-assembly and vesicle characteristics were controlled by surfactant/cholesterol/charge composition. Surface modification prolonged circulation halflife, augmented tumour accumulation and intracellular delivery, and minimized off-targeting and immunogenicity. Functional developments allowed systemic delivery of chemotherapeutics and biologics, co-delivery with nucleic acids (siRNA, CRISPR-Cas9), and theranostic integration with imaging agents. Compared with peer platforms, proniosomes equalled or surpassed drug loading, stability, and systemic bioavailability, and the dry format minimized manufacturing and scale-up. Modularity of the platform facilitates targeted, multi-functional regimens and individualized dosing, providing a pragmatic path to precision oncology. Issues remaining are regulatory routes, batch reproducibility, and industrial scale-up.
- 16 March 2026
- Published by Bentham Science Publishers Ltd. in Current Nanomedicine
- Vol. 16, 1-13
Clinical Translation Potential of Surface-Modified Proniosomes in Systemic Cancer Therapeutics
Proniosomes are anhydrous, non-ionic surfactant precursors that rehydrate into bilayered niosomes, addressing long-standing challenges in systemic cancer drug delivery. We systematically reviewed oncology-targeted proniosome publications, comparing drug loading, stability, release, and pharmacokinetics with liposomes, polymeric nanoparticles, micelles, and solid-lipid nanoparticles. We assessed design determinants (surfactant composition, cholesterol ratio, charge inducers), surface modifications (PEGylation, ligand conjugation, pH- or thermoresponsive groups), and conducted a SWOT analysis. Proniosomes demonstrated high physicochemical stability, robust encapsulation, and controlled release, supporting hydrophilic, hydrophobic, and macromolecular payloads. Self-assembly and vesicle characteristics were controlled by surfactant/cholesterol/charge composition. Surface modification prolonged circulation halflife, augmented tumour accumulation and intracellular delivery, and minimized off-targeting and immunogenicity. Functional developments allowed systemic delivery of chemotherapeutics and biologics, co-delivery with nucleic acids (siRNA, CRISPR-Cas9), and theranostic integration with imaging agents. Compared with peer platforms, proniosomes equalled or surpassed drug loading, stability, and systemic bioavailability, and the dry format minimized manufacturing and scale-up. Modularity of the platform facilitates targeted, multi-functional regimens and individualized dosing, providing a pragmatic path to precision oncology. Issues remaining are regulatory routes, batch reproducibility, and industrial scale-up.